Valeant Surges on Higher Profit Forecast, Outlook for More Deals

Valeant Pharmaceuticals International Inc. shares jumped the most in more than three months after boosting its forecast for profit this year and predicting a steady flow of acquisitions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.